Kidney Transplant Drugs Receive New Warnings About Infection Side Effects

The FDA is requiring new warnings on several immunosuppressant drugs designed to prevent renal transplant patients from rejecting new kidneys. The new labeling will warn users of potential side effects that may increase the risk of infections due to a suppressed immune system.

According to an FDA alert issued Tuesday, the immunosuppressant drugs affected by the new warnings include Rapamune (sirolimus), Sandimmune (cyclosporine) and its generics, Neoral (cyclosporine modified) and its generics, CellCept (mycophenolate mofetil) and its generics, and Myfortic (mycophenolic acid). A similar warning is already in place on the label for the immunosuppressant drug Prograf (tacrolimus).

Immunosuppressant drugs are prescribed to transplant patients to prevent the body’s immune system from attacking new organs, which are often recognized by the body as foreign invaders. However, the FDA indicates that depressing the immune system leaves patients at risk for opportunistic infections, which could cause serious injury or death to the patient.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The FDA announcement says kidney transplant patients were especially vulnerable, and indicates that monitoring for this serious risk is critical.

Some of the immunosuppressant drugs already contain warnings information about the infection risk, as well as warnings about other serious side effects.

In July 2008, new warnings were added about potential CellCept and Myfortic side effects which could increase the risk of progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection that attacks the white matter areas of the brain. In addition, a “black box” warning, which is the most stringent warning possible under federal regulations, was added to the drugs in November 2007 indicating a potential risk of Myfortic and CellCept birth defects, such as cleft palate, cleft lip and ear deformities, when taken during pregnancy.

Last month the FDA issued a warning to transplant doctors that switching patients to Rapamune after a liver transplant may increase the risk of death. The warning came after a recent study by the manufacturer, Wyeth, revealed that the chance of liver rejection was “significantly higher” for stable liver transplant patients who switched to Rapamune after first using a calcineurin inhibitor (CNI)-based immunosuppressive treatment.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.